Publications

PUBLICATIONS | ABSTRACTS

New England Journal of Medicine

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

This Genentech sponsored study demonstrated the clinical utility of blood-informed PredicineBEACON™ MRD ctDNA and PredicineWES+™ assays for target engagement, therapy monitoring, and resistance mechanism study in NSCLC, colorectal cancer, and other cancers.

August 2023

Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

Using PredicineBEACON™ to demonstrate the potential for tissue-agnostic tumor-informed, urine-based MRD assay to inform clinical decision-making around organ-preserving opportunities and may fundamentally transform healthcare guidelines for MIBC patients

August 2023

Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial

In this new study, PredicineATLAS™ was used to assess the predictive utility of longitudinal circulating tumor DNA (ctDNA) analysis from a single-institution biomarker cohort.

August 2023

Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy

PredicineATLAS™ was used to assess the ability of cell-free urinary and plasma tumor DNA (cfDNA) to predict pathologic stage at radical cystectomy for patients with clinical muscle-invasive bladder cancer.

August 2023

Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer

In this research study, machine learning models were established that provide significant prognostic prediction of metastatic prostate cancer (mPC) clinical outcomes from blood-based multi-omic data. Plasma ctDNA alterations in combination with plasma lipid species measurements were used to identify a molecular classifier in different states of mPC progression.

August 2023

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

In this research study, PredicineCARE™ was used to for targeted sequencing on 407 plasma samples from 375 men with mCRPC.

August 2023

Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features

Using PredicineCARE™ to perform comprehensive genomic profiling on DNA extracted from formalin-fixed, paraffin-embedded samples.

June 2023

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

PredicineCARE™ was utilized to analyze plasma samples to assess somatic circulating tumor DNA (ctDNA) alterations.

June 2023

Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

In this research study, PredicineWES™ boosted whole exome sequencing was used to analyze circulating tumor DNA (ctDNA) to identify genomic features for predicting and monitoring treatment resistance.

January 2023

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

PredicineATLAS™ liquid biopsy next-generation sequencing assay was used to compare gemcitabine and nab-paclitaxel with and without immune checkpoint inhibitors durvalumab and tremelimumab in 180 patients with mPDAC. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and objective response rate.

August 2022

Identification of mutation patterns and circulating tumour DNA-derived prognostic markets in advanced breast cancer patients

Using PredicineCARE™ liquid biopsy next-generation sequencing assay, assessment were done on the correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response and survival outcome in Chinese patients with advanced breast cancer (ABC).

May 2022

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels

In this research study, PredicineATLAS™ (Assay B) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to four other leading commercial liquid biopsy assays.

May 2022

Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer

The PredicineATLAS™ panel was used to detect germline variants in Chinese patients with advanced breast cancer.

April 2022

Gemcitabine and Cisplatin Plus Durvalumad With or Without Tremelimumad in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study

In this study, PredicineATLAS™ liquid biopsy study is used to evaluate gemcitabine and cisplatin plus durvalub with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.

March 2022

Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer

In this study, PredicineCARE™ is used to evaluate circulating tumor DNA (ctDNA) in blood or urine, which can be used as biomarkers of PCa and the combination of these markers may increase the sensitivity and specificity of the detection of PCa.

March 2022

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

In this study, PredicineCARE™ is used to perform a retrospective analysis of serially profiled cell-free DNA (cfDNA) alterations in blood samples collected from mCRPC patients before and after starting chemotherapy who were followed for response and clinical outcomes.

March 2022

Combined impact of lipidomic and genetic aberrations on clinicaloutcomes in metastatic castration-resistant prostate cancer

In this study, Predicine’s GeneRADAR technology and DeepSea machine learning is used to assess the association between the poor prognostic 3-lipid signature (3LS), somatic genetic aberrations and clinical outcomes in mCRPC.

March 2022

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Predicine’s cfDNA and cfRNA assays were utilized to assess the role of somatic alterations on treatment resistance in patients with metastatic castration-resistant prostate cancer.

October 2021

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Utilizing the PredicineCARE™ assay, this study demonstrates that urinary tumor DNA (utDNA) outperformed circulating tumor DNA (ctDNA) from blood samples in identifying somatic alterations in patients with newly diagnosed urothelial bladder cancer.

September 2021

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China

The PredicineCARE™ liquid biopsy assay was utilized to evaluate the correlation between genomic alterations and progression-free survival in patients with hormone-receptor positive metastatic breast cancer in the US and China

September 2021

Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial

In a study, the PredicineCARE™ and PredicineRNA™ liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.

September 2021

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

The PredicineCARE™ liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.

August 2021

Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

Using PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.

May 2021

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.

April 2021

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.

April 2021

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

Using PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.

November 2020

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.

November 2020

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.

May 2020

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.

May 2020

Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.

April 2020

Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.

February 2020

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.

January 2020

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.

December 2019

2023 ASCO ANNUAL MEETING

Urine-based epigenetic profiling for detection of clear cell renal cell carcinoma: A prospective study.

Wen Kong, Jin Zhang, Hang Dong, Haoran Tang, Pan Du, Shidong Jia

June 2023

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.

Kyle Rose, Prithvi Murthy, Billie Gould, Heather Huelster, Facundo Davaro, Lucia Camperlengo, Pan Du, Shidong Jia, Aram Vosoughi, G. Daniel Grass, Philippe Spiess, Scott Gilbert, Wade Sexton, Roger Li

June 2023

Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.

Jie Hu, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, Jian Zhou

June 2023

Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study.

Ruiyun Zhang, Jingyu Zang, Haoran Tang, Feng Xie, Yue Zhang, Di Jin, Lei Qian, Tianxiang Zhang, Shidong Jia, Guanglei Zhuang, Haige Chen

June 2023

Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

– Collaboration with Dana Farber

April 2023

Prostatic fluid-based cfDNA methylation profiling distinguish benign hyperplasia from prostate cancer

Hang Dong, Haoran Tang, Yue Zhang, Shidong Jia

April 2023

Liquid biopsy-based comprehensive genomic profiling reveal mutational landscape in real-world patients with unresectable NSCLC

Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia

April 2023

Comparative genomic profiling and disease monitoring in unresectable gastric and colon cancer

Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia

April 2023

Liquid biopsy-based comprehensive genomic profiling reveal mutational landscape in advanced breast cancer

Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia

April 2023

Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients

Jie Hu, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, Jian Zhou

April 2023

Adverse clinical outcomes and distinct genomic phenotype of BRCA-deficient metastatic castration-resistant prostate cancer (mCRPC)

Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Winston Tan, P. Du, Nicole Ng, Patricia Bukszynska, Maria Docanto, L. K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad

April 2023

Targeted liquid biopsy mutation profiling and genome-wide cfDNA copy-number landscape in 3000 samples from six major cancer indications

Billie Gould, Lu Tan, Chao Dai, Tiantian Zheng, Wei Mo, Xianghong Wang, Michael Sneddon, Shidong Jia, Kemin Zhou, Pan Du

April 2023

The development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers

Giancarlo Bonora, Hang Dong, Chao Dai, Binggang Xiang, Billie Gould, Tiantian Zhen, Wei Mo, Xiaohong Wang, Kemin Zhou, Shidong Jia, Shujun Luo, Pan Du

April 2023

Comparative analysis of blood-based tumor fraction estimation in 300 cancer patients

Chao Dai, Tiantian Zheng, Xiaoxi Dong, Wei Mo, Xiaohong Wang, Shujun Luo, Kemin Zhou, Shidong Jia, Pan Du

April 2023

Development of a novel urine cell-free DNA preservation method for molecular profiling in genitourinary tumors

Jie Zhang, Fang Liu, Min Wang, Cuishan Deng, Wei Mo, Seng Tao, Amy Wang, Shidong Jia, Zhixin Zhao, Pan Du, Binggang Xiang, Shujun Luo

April 2023

Development of a rapid, highly sensitive cell-free RNA NGS assay for the detection of gene fusion and splicing variants in cancers

Fang Liu, Xiangying Sun, Jianrong Dong, Kemin Zhou, Yong Huang, Shidong Jia, Pan du, Binggang Xiang, Shujun Luo

April 2023

Evaluating technical feasibility of a urine cell-free DNA (cfDNA) NGS assay for identifying biomarkers in bladder cancer.

Il-Jin Kim, Michelle Quiroz, Zhixin Zhao, Wei Mo, Tiantian Zheng, Amy Wang, Usha Singh, Neil Beeharry, Denis Smirnov, Songbai Wang, Renee Tate, Tom Zhang, Fang Liu, Seema Hanumanthe, Binggang Xiang, Shujun Luo, Alexander Kuklin, Ralph M. Wirtz, Pan Du, Shidong Jia

February 2023

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: A prospective study.

Kyle M. Rose, Prithvi Murthy, Billie Gould, Heather L Huelster, Facundo Davaro, Pan Du, Shidong Jia, Roger Li

February 2023

Clinical applications of urine- and blood-based genome wide copy number study from 1,000 patients with bladder and prostate cancer.

Chao Dai, Tiantian Zheng, Wei Mo, Giancarlo Bonora, Amy Wang, Shujun Luo, Kemin Zhou, Shidong Jia, Pan Du

February 2023

Diagnosis of prostate cancer using cell-free DNA methylation profiles from expressed prostatic secretions.

Wenhao Shen, Hang Dong, Haoran Tang, Yue Zhang, Shidong Jia, Yang Luo

February 2023

Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha

Nathan Standifer, PhD; Yonchu Jenkins; Sam H. Whiting, MD, PhD; Thomas W. Dubensky, Jr., PhD;

November 2022

Evaluation of liquid biopsy-based plasma Copy Number Burden, DNA methylation and personalized minimal residual disease approach for monitoring molecular response to different drug regimens in metastatic colorectal cancer

Zheng Feng, PhD, MD; Neil R. Smith, PhD; Giancarlo Bonora, PhD; Juergen Scheuenpflug; Pan Du

November 2022

2022 ESMO

Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing

Jingyu Zhang, Ruiyun Zhang, Feng Xie, Yue Zhang, Pan Du, Shidong Jia, Haige Chen, Guanglei Zhuang

September 2022

Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition

Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Shana Thomas, Lindsay Peterson, Xiaohong Wang, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma

September 2022

The development and application of a baseline-agnostic minimal residual disease assay

Roger Li, Giancarlo Bonora, Chao Dai, Binggang Xiang, Hang Dong, Wei Mo, Xiaohong Wang, Kemin Zhou, Shidong Jia, Shujun Luo, Pan Du

September 2022

Comprehensive genomic profiling NSCLC patients with leptomeningeal metastases through circulating tumor DNA in cerebrospinal fluid

Sen Yang, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, Qiming Wang

September 2022

Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma

Heather L Huelster, Elizabeth A. Green, Alex C. Soupir, Kyle M. Rose, Esther N. Katende, Shreyas U Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Alice Yu, Philippe E. Spiess, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li

May 2022

Molecular characterization of renal cell carcinoma with venous tumor thrombus: Genomic aberrations with renal vein wall invasion.

Xiaoxi Dong, Cheng Liu, Shidong Jia, Jianjun Yu, Lulin Ma

February 2022

Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma.

Heather Huelster, Elizabeth A. Green, Alex C. Soupir, Esther N. Katende, Kyle M. Rose, Shreyas U. Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Philippe E. Spiess, Alice Yu, Youngchul Kim, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li

February 2022

Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).ment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).

Heidi Fettke, Christine Hauser, Edmond Kwan, Chao Dai, Tiantian Zheng, Amy Wang, Winston Tan, Pan Du, Nicole Ng, Patricia Bukczynska, Siavash Foroughi, Lisa-Jane K. Graham, Lisa Horvath, Kate Lynette Mahon, Shidong Jia, Manish Kohli, Arun Azad

February 2022

Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).

Andrea Knox, Heidi Fettke, Christine Hauser, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K. Graham, Kate Lynette Mahon, Winston Tan, Tiantian Zheng, Chao Dai, Pan Du, Shidong Jia, Lisa Horvath, Manish Kohli, Arun Azad, Edmond Kwan, Amy Wang

February 2022

Longitudinal personalized urinary tumor DNA analysis in muscle-invasive bladder cancer from the neoadjuvant immunotherapy trial RJBLC-I2N003.

Ruiyun Zhang, Jingyu Zang, Feng Xie, Yue Zhang, Akezhouli Shahatiaili, Yiqiu Wang, Pan Du, Shidong Jia, Guanglei Zhuang, Yiran Huang, Haige Chen

February 2022

Development and clinical application of PredicineBEACON next-generation minimal residual disease assay for genitourinary cancers.

Feng Xie, Jingyu Zang, Yue Zhang, Ruiyun Zhang, Yong Huang, Guanglei Zhuang, Haige Chen, Pan Du, Shidong Jia

February 2022

Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genomewide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormonereceptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)

December 2021

Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance

Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli

December 2019

Blood-based detection of PTEN loss and pathway alterations for personalized treatment of breast cancer

Pan Du, Eric Jia and Zhixin Zhao

December 2019

Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA

Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli

December 2019

Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee

June 2019

Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy response

Jianjun Yu, Jianguo Dong, Amy Wang, Joseph S. Krueger

April 2019

Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients

Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad

April 2019

Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in immuno-oncology

Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du

April 2019

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer

Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu

February 2019

Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients

Yu J, Li H, Zhang S, Wang A, Zhao Z

December 2018

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.

PUBLICATIONS | ABSTRACTS

Publications

New England Journal of Medicine

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Clinical Cancer Research

Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

Journal of Pathology

Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial

Société Internationale d'Urologie Journal

Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy

JCO Clinical Cancer Informatics

Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer

eBioMedicine

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

The American Journal of Surgical Pathology

Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features

Frontiers in Oncology

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

CLINICAL CANCER RESEARCH

Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

NATURE COMMUNICATIONS

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

BMC Journal of Translational Medicine

Identification of mutation patterns and circulating tumour DNA-derived prognostic markets in advanced breast cancer patients

PLOS ONE

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels

Frontiers in Oncology

Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer

THE LANCET GASTROENTEROLOGY HEPATOLOGY

Gemcitabine and Cisplatin Plus Durvalumad With or Without Tremelimumad in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study

Frontiers in Oncology

Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer

Scientific Reports

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

BMC Medicine

Combined impact of lipidomic and genetic aberrations on clinicaloutcomes in metastatic castration-resistant prostate cancer

EBioMedicine

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

The Journal of Urology

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Breast Cancer Research and Treatment

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China

European Urology

Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial

Frontiers in Oncology

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

Fortune Journals

Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

Cancer Management and Research

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

JCO Precision Oncology

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

The Breast

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

Blood

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

European Urology

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

European Urology

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

EBioMedicine

Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Chinese Journal of Cancer Research

Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

Critical Reviews in Oncology

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

BREAST CANCER RESEARCH

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Abstracts

2023 ASCO ANNUAL MEETING

Urine-based epigenetic profiling for detection of clear cell renal cell carcinoma: A prospective study.

2023 ASCO ANNUAL MEETING

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.

2023 ASCO ANNUAL MEETING

Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.

2023 ASCO ANNUAL MEETING

Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study.

2023 AACR

Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

2023 AACR